Drug reference

Magnesium glycerophosphate

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1134

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Prevent recurrence of magnesium deficit ▶BY MOUTH ▶Adult: 24 mmol daily in divided doses, dose expressed as Mg2+ DOSE EQUIVALENCE AND CONVERSION ▶Magnesium glycerophosphate 1 g is approximately equivalent to Mg2+ 4 mmol or magnesium 97 mg. NEOMAG ® CHEWABLE TABLETS Hypomagnesaemia ▶BY MOUTH ▶Adult: Initially 1–2 tablets 3 times a day, dose to be adjusted according to the serum total magnesium level DOSE EQUIVALENCE AND CONVERSION ▶Each Neomag ® chewable tablet contains Mg2+ 4 mmol or magnesium 97 mg. l UNLICENSED USE Preparations other than Neomag ® are not licensed for use.

PDF page 1134

National Funding Access Decisions

NEOMAG ® CHEWABLE TABLETS Scottish Medicines Consortium (SMC) decisions The Scottish Medicines Consortium has advised (September 2017) that magnesium glycerophosphate (Neomag ®) is accepted for use within NHS Scotland as an oral magnesium supplement for the treatment of patients with chronic magnesium loss, hypomagnesaemia or drug- induced hypomagnesaemia.

PDF page 1134

Safety

Interactions

→Appendix 1: magnesium

PDF page 1134

Side Effects

Diarrhoea. hypermagnesaemia Overdose Symptoms of hypermagnesaemia may include nausea, vomiting, ﬂushing, thirst, hypotension, drowsiness, confusion, reﬂexes absent (due to neuromuscular blockade), respiratory depression, speech slurred, diplopia, muscle weakness, arrhythmias, coma, and cardiac arrest.

PDF page 1134

Renal Impairment

Increased risk of toxicity. Dose adjustments Avoid or reduce dose. NEOMAG ® CHEWABLE TABLETS Manufacturer advises avoid in severe impairment.

PDF page 1134

Monitoring Requirements

Manufacturer advises to monitor serum magnesium levels every 3–6 months.

PDF page 1134

Dose and formulations

Directions For Administration

NEOMAG ® CHEWABLE TABLETS Manufacturer advises that tablets may be broken into quarters and chewed or swallowed with water.

PDF page 1134

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: tablet, capsule, oral suspension, oral solution, powder Tablet ▶Mag-4 (Ennogen Healthcare Ltd) Magnesium (as Magnesium glycerophosphate) 97.2 mg Mag-4 (magnesium 97.2mg (4mmol)) tablets | 30 tablet £84.50 Oral solution ▶LiquaMag GP (Fontus Health Ltd) Magnesium (as Magnesium glycerophosphate) 24.25 mg per 1 ml LiquaMag GP (magnesium 121.25mg/5ml (5mmol/5ml)) oral solution sugar-free | 200 ml £49.99 ▶MagnaPhos (TriOn Pharma Ltd) Magnesium (as Magnesium glycerophosphate) 19.44 mg per 1 ml MagnaPhos 97.2mg/5ml (4mmol/5ml) oral solution | 200 ml £37.87 DT = £41.97 Magnesium (as Magnesium glycerophosphate) 24.25 mg per 1 ml MagnaPhos 121.25mg/5ml (5mmol/5ml) oral solution | 200 ml £37.87 DT = £37.87 Chewable tablet EXCIPIENTS: May contain Aspartame ▶Magnesium glycerophosphate (Non-proprietary) Magnesium glycerophosphate (magnesium 97.2mg (4mmol)) chewable tablets sugar-free | 50 tablet P £22.77 DT = £22.77 ▶Neomag (Neoceuticals Ltd) Magnesium (as Magnesium glycerophosphate) 97.2 mg Neomag (magnesium 97mg (4mmol)) chewable tablets | 50 tablet P £22.77 DT = £22.77 Capsule ▶MagnEss Gly (Essential-Healthcare Ltd) Magnesium (as Magnesium glycerophosphate) 39.5 mg MagnEss Gly 39.5mg (1.6mmol) capsules | 50 capsule £28.17 Magnesium (as Magnesium glycerophosphate) 48.6 mg MagnEss Gly 48.6mg (2mmol) capsules | 50 capsule £25.97 Magnesium (as Magnesium glycerophosphate) 97.2 mg MagnEss Gly 97.2mg (4mmol) capsules | 50 capsule £27.83 ▶MagnaPhos (TriOn Pharma Ltd) Magnesium (as Magnesium glycerophosphate) 48.6 mg MagnaPhos 48.6mg (2mmol) capsules | 50 capsule £28.86 Magnesium (as Magnesium glycerophosphate) 97.2 mg MagnaPhos 97.2mg (4mmol) capsules | 50 capsule £31.86

PDF page 1134

Dose text by age group

Adult

24 mmol daily in divided doses, dose expressed

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1134

Adult

Initially 1–2 tablets 3 times a day, dose to be

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1134

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Magnesium glycerophosphate

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1134

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 1134

National Funding Access Decisions

PDF page 1134

Safety

Interactions

→Appendix 1: magnesium

PDF page 1134

Side Effects

PDF page 1134

Renal Impairment

Increased risk of toxicity. Dose adjustments Avoid or reduce dose. NEOMAG ® CHEWABLE TABLETS Manufacturer advises avoid in severe impairment.

PDF page 1134

Monitoring Requirements

Manufacturer advises to monitor serum magnesium levels every 3–6 months.

PDF page 1134

Dose and formulations

Directions For Administration

NEOMAG ® CHEWABLE TABLETS Manufacturer advises that tablets may be broken into quarters and chewed or swallowed with water.

PDF page 1134

Medicinal Forms

PDF page 1134

Dose text by age group

Adult

24 mmol daily in divided doses, dose expressed

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1134

Adult

Initially 1–2 tablets 3 times a day, dose to be

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1134

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.